Our client was launching a novel therapy for the treatment of Ulcerative Colitis (UC) and wanted to assess the strategic potential of patient affordability solutions across 13 international markets

The client had developed and launched a human papillomavirus (HPV) vaccine which was reimbursed for adolescents through national immunization programs for only some markets

The client developed an innovative treatment for sickle cell disease (SCD) and wanted to assess the payer and self-pay landscape, understand barriers to funding / purchase decisions, and identify affordability solutions to support access to Product X across markets in-scope

The client was preparing for an indication expansion of Product X, which was already indicated in other blood conditions, into alpha-thalassemia, an inherited blood disorder

A global pharmaceutical company was preparing to file a reimbursement dossier for the prevention of migraine in Canada and Europe.

Our client had recently received EMA approval for a novel androgen receptor inhibitor, indicated within several solid tumors.

Our client had a Phase III biosimilar for the treatment of febrile neutropenia in the pipeline, with an estimated 5-years to launch

Our client had a late-stage vaccine candidate targeting older adult (OA) respiratory syncytial virus (RSV), and wanted support with its US pricing and access strategy.

A global pharmaceutical company had a Phase II/III enzyme replacement therapy in development for a rare genetic disorder that targeted symptoms not addressed by current standard of care.

Windrose conducted a pricing, market access and evidence gap assessment across US, EU4 and UK for two novel agents in a muscle weakness disorder

Our client was evaluating an orphan indication for Product X, which is currently indicated for another orphan indication in Europe, Japan, and Latin America.

Our client has a successful JAK inhibitor, “Product X”, which has large volumes of sales in the US; Product X sales are expected to continue to grow in the EU5, particularly through indication expansion.

Our client had a novel oral anticoagulant (NOAC) indicated for thromboembolic disorders on the market, which had seen significant commercial success and sales growth since its launch.

Our client had to make a business development decision regarding a potential new asset which would be developed in ulcerative colitis (UC) and atopic dermatitis (AtD).

Our client wanted to understand the non-muscle invasive bladder cancer (NMIBC) disease landscape, specifically for high-risk patients unresponsive to current non-surgical standard of care, for Germany, France, and Canada.

A global pharmaceutical company was exploring a potential partnership with one of several companies developing a new anti-CGRP to treat and prevent migraines

Product X is seeking approval in locally advanced or metastatic urothelial carcinoma (i.e. bladder cancer) as a monotherapy and as a 2nd Line (2L) option

Product X is expected to gain accelerated approval based on an open label, single-arm Phase II study

Objective: Develop a clear understanding of US payer perceptions of key value drivers and potential price ranges, and to form the basis for preliminary payer value story and proposition

A global pharmaceutical company was developing a new product for the treatment of Parkinson’s disease; the product had a novel mechanism of action and was in early phase of clinical development

A global pharmaceutical company’s R&D portfolio included several combination products across multiple different disease states.

A biopharmaceutical company was developing the first gene therapy for a rare disease. It was expected to be a one-time therapy that would replace the current chronic standard of care.